Publications

Diffuse large B cell lymphoma (DLBCL) is the commonest type of non-Hodgkin lymphoma (NHL) in adults, accounting for around 30 to 35% of all NHL cases.[1] [2] With current standards of care, up to 50 to 70% of these patients can achieve a lasting remission.[1] Of the remaining patients, the relapsed/refractory cases, cure is only possible in 10%, even with further lines of therapy or stem cell transplant.[1] This heterogeneity in DLBCL?s clinical behavior reflects the underlying molecular heterogeneity of the disease. Thankfully, we are now able to understand this heterogeneity a little better and subtype DLBCL cases based on immunohistochemistry (IHC) and molecular markers, enabling us to have deeper prognostic insights and helping us to make therapeutic decisions. The various classification systems in use for DLBCL include the ?cell-of-origin? (COO) classification, the comprehensive consensus clustering classification, double-hit/triple-hit lymphomas (DHL/THL), double-expressor lymphomas (DEL), and the modern classification.